Hence, our study has identified Survivin as a potential novel molecular target of Nef in PCa cells, which needs further validation in order to develop Nef as a clinically viable antitumor drug due to the differential expression of Survivin in malignant versus normal cells. Here, S100B is linked to posterior cortical atrophy.